NCT00645502: Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet. |
|
|
| Completed | 1 | 40 | US | risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia, Schizoaffective Disorders | | 07/03 | | |
NCT00796185: As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations |
|
|
| Completed | 1 | 62 | US | Paliperidone ER | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia, Schizoaffective Disorder | | 01/04 | | |
NCT00821600: Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia |
|
|
| Completed | 1 | 24 | US | risperidone IR and LAI formulation | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Psychotic Disorders, Schizophrenia | 06/09 | 06/09 | | |
NCT02087579: Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants |
|
|
| Completed | 1 | 305 | US, Europe, RoW | Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, INVEGA®, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, RISPERDAL®, Risperidone, LAI | Janssen Research & Development, LLC | Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder | 10/14 | 12/14 | | |